Fundamental Analysis of CITIUS PHARMACEUTICALS INC(NASDAQ:CTXR) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to CTXR. CTXR was compared to 198 industry peers in the Pharmaceuticals industry. CTXR has a great financial health rating, but its profitability evaluates not so good. CTXR does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

CTXR had negative earnings in the past year.

In the past year CTXR has reported a negative cash flow from operations.

In the past 5 years CTXR always reported negative net income.

In the past 5 years CTXR always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -40.39%, CTXR is in line with its industry, outperforming 48.72% of the companies in the same industry.

CTXR has a Return On Equity (-46.42%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-40.39%
ROE	-46.42%
ROIC	N/A

ROA(3y)-26.41%

ROA(5y)-32.34%

ROE(3y)-29.45%

ROE(5y)-39.53%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTXR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CTXR has more shares outstanding than it did 1 year ago.

CTXR has more shares outstanding than it did 5 years ago.

CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 1.51, we must say that CTXR is in the distress zone and has some risk of bankruptcy.

CTXR has a Altman-Z score of 1.51. This is in the better half of the industry: CTXR outperforms 65.64% of its industry peers.

CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1.51

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 5.06 indicates that CTXR has no problem at all paying its short term obligations.

CTXR has a Current ratio of 5.06. This is in the better half of the industry: CTXR outperforms 65.64% of its industry peers.

CTXR has a Quick Ratio of 5.06. This indicates that CTXR is financially healthy and has no problem in meeting its short term obligations.

CTXR's Quick ratio of 5.06 is fine compared to the rest of the industry. CTXR outperforms 67.18% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.06
Quick Ratio	5.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CTXR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.27%.

EPS 1Y (TTM)-43.27%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-190.35%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

CTXR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.80% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-31.25%

EPS Next 2Y66.77%

EPS Next 3Y75.85%

EPS Next 5Y62.8%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTXR. In the last year negative earnings were reported.

CTXR is valuated cheaply with a Price/Forward Earnings ratio of 5.43.

Based on the Price/Forward Earnings ratio, CTXR is valued cheaper than 97.95% of the companies in the same industry.

When comparing the Price/Forward Earnings ratio of CTXR to the average of the S&P500 Index (21.32), we can say CTXR is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.43

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CTXR's earnings are expected to grow with 75.85% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y66.77%

EPS Next 3Y75.85%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CTXR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (4/29/2024, 7:00:01 PM)

After market: 0.6951 +0 (+0.45%)

0.692

+0.03 (+4.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap110.09M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.43
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-40.39%
ROE	-46.42%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.06
Quick Ratio	5.06
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-43.27%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-31.25%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CITIUS PHARMACEUTICALS INC (CTXR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens